Cargando…
Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
RATIONALE: In patients with biochemical recurrence of prostate cancer (BCR), preliminary data suggest that prostate-specific membrane antigen (PSMA) ligand radiotracers labeled with zirconium-89 ((89)Zr; half-life ~ 78.41 h), which allow imaging ≥ 24 h post-injection, detect suspicious lesions that...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317886/ https://www.ncbi.nlm.nih.gov/pubmed/37148297 http://dx.doi.org/10.1007/s00259-023-06241-0 |
_version_ | 1785067920319053824 |
---|---|
author | Rosar, Florian Khreish, Fadi Marlowe, Robert J. Schaefer-Schuler, Andrea Burgard, Caroline Maus, Stephan Petto, Sven Bartholomä, Mark Ezziddin, Samer |
author_facet | Rosar, Florian Khreish, Fadi Marlowe, Robert J. Schaefer-Schuler, Andrea Burgard, Caroline Maus, Stephan Petto, Sven Bartholomä, Mark Ezziddin, Samer |
author_sort | Rosar, Florian |
collection | PubMed |
description | RATIONALE: In patients with biochemical recurrence of prostate cancer (BCR), preliminary data suggest that prostate-specific membrane antigen (PSMA) ligand radiotracers labeled with zirconium-89 ((89)Zr; half-life ~ 78.41 h), which allow imaging ≥ 24 h post-injection, detect suspicious lesions that are missed when using tracers incorporating short-lived radionuclides. MATERIALS AND METHODS: To confirm [(89)Zr]Zr-PSMA-617 positron emission tomography/computed tomography (PET/CT) detection efficacy regarding such lesions, and compare quality of 1-h, 24-h, and 48-h [(89)Zr]Zr-PSMA-617 scans, we retrospectively analyzed visual findings and PET variables reflecting lesional [(89)Zr]Zr-PSMA-617 uptake and lesion-to-background ratio. The cohort comprised 23 men with BCR post-prostatectomy, median (minimum–maximum) prostate-specific antigen (PSA) 0.54 (0.11–2.50) ng/mL, and negative [(68)Ga]Ga-PSMA-11 scans 40 ± 28 d earlier. Primary endpoints were percentages of patients with, and classifications of, suspicious lesions. RESULTS: Altogether, 18/23 patients (78%) had 36 suspicious lesions (minimum–maximum per patient: 1–4) on both 24-h and 48-h scans (n = 33 lesions) or only 48-h scans (n = 3 lesions). Only one lesion appeared on a 1-h scan. Lesions putatively represented local recurrence in 11 cases, and nodal or bone metastasis in 21 or 4 cases, respectively; 1/1 lesion was histologically confirmed as a nodal metastasis. In all 15 patients given radiotherapy based on [(89)Zr]Zr-PSMA-617 PET/CT, PSA values decreased after this treatment. Comparison of PET variables in 24-h vs 48-h scans suggested no clear superiority of either regarding radiotracer uptake, but improved lesion-to-background ratio at 48 h. CONCLUSIONS: In men with BCR and low PSA, [(89)Zr]Zr-PSMA-617 PET/CT seems effective in finding prostate malignancy not seen on [(68)Ga]Ga-PSMA-11 PET/CT. The higher detection rates and lesion-to-background ratios of 48-h scans versus 24-h scans suggest that imaging at the later time may be preferable. Prospective study of [(89)Zr]Zr-PSMA-617 PET/CT is warranted. |
format | Online Article Text |
id | pubmed-10317886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-103178862023-07-05 Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer Rosar, Florian Khreish, Fadi Marlowe, Robert J. Schaefer-Schuler, Andrea Burgard, Caroline Maus, Stephan Petto, Sven Bartholomä, Mark Ezziddin, Samer Eur J Nucl Med Mol Imaging Original Article RATIONALE: In patients with biochemical recurrence of prostate cancer (BCR), preliminary data suggest that prostate-specific membrane antigen (PSMA) ligand radiotracers labeled with zirconium-89 ((89)Zr; half-life ~ 78.41 h), which allow imaging ≥ 24 h post-injection, detect suspicious lesions that are missed when using tracers incorporating short-lived radionuclides. MATERIALS AND METHODS: To confirm [(89)Zr]Zr-PSMA-617 positron emission tomography/computed tomography (PET/CT) detection efficacy regarding such lesions, and compare quality of 1-h, 24-h, and 48-h [(89)Zr]Zr-PSMA-617 scans, we retrospectively analyzed visual findings and PET variables reflecting lesional [(89)Zr]Zr-PSMA-617 uptake and lesion-to-background ratio. The cohort comprised 23 men with BCR post-prostatectomy, median (minimum–maximum) prostate-specific antigen (PSA) 0.54 (0.11–2.50) ng/mL, and negative [(68)Ga]Ga-PSMA-11 scans 40 ± 28 d earlier. Primary endpoints were percentages of patients with, and classifications of, suspicious lesions. RESULTS: Altogether, 18/23 patients (78%) had 36 suspicious lesions (minimum–maximum per patient: 1–4) on both 24-h and 48-h scans (n = 33 lesions) or only 48-h scans (n = 3 lesions). Only one lesion appeared on a 1-h scan. Lesions putatively represented local recurrence in 11 cases, and nodal or bone metastasis in 21 or 4 cases, respectively; 1/1 lesion was histologically confirmed as a nodal metastasis. In all 15 patients given radiotherapy based on [(89)Zr]Zr-PSMA-617 PET/CT, PSA values decreased after this treatment. Comparison of PET variables in 24-h vs 48-h scans suggested no clear superiority of either regarding radiotracer uptake, but improved lesion-to-background ratio at 48 h. CONCLUSIONS: In men with BCR and low PSA, [(89)Zr]Zr-PSMA-617 PET/CT seems effective in finding prostate malignancy not seen on [(68)Ga]Ga-PSMA-11 PET/CT. The higher detection rates and lesion-to-background ratios of 48-h scans versus 24-h scans suggest that imaging at the later time may be preferable. Prospective study of [(89)Zr]Zr-PSMA-617 PET/CT is warranted. Springer Berlin Heidelberg 2023-05-06 2023 /pmc/articles/PMC10317886/ /pubmed/37148297 http://dx.doi.org/10.1007/s00259-023-06241-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Rosar, Florian Khreish, Fadi Marlowe, Robert J. Schaefer-Schuler, Andrea Burgard, Caroline Maus, Stephan Petto, Sven Bartholomä, Mark Ezziddin, Samer Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer |
title | Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer |
title_full | Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer |
title_fullStr | Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer |
title_full_unstemmed | Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer |
title_short | Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer |
title_sort | detection efficacy of [(89)zr]zr-psma-617 pet/ct in [(68)ga]ga-psma-11 pet/ct-negative biochemical recurrence of prostate cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317886/ https://www.ncbi.nlm.nih.gov/pubmed/37148297 http://dx.doi.org/10.1007/s00259-023-06241-0 |
work_keys_str_mv | AT rosarflorian detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer AT khreishfadi detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer AT marlowerobertj detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer AT schaeferschulerandrea detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer AT burgardcaroline detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer AT mausstephan detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer AT pettosven detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer AT bartholomamark detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer AT ezziddinsamer detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer |